Skip to main content

Table 2 PICO criteria

From: High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis

PICO

Inclusion Criteria

Participants

• Persons with knee OA

Interventions

• Intraarticular corticosteroids

o Triamcinolone

o Methylprednisolone

o Betamethasone

o Triamcinolone Sustained Release

• Intraarticular Hyaluronic Acids

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

o Diclofenac

o Celecoxib

o Naproxen

• Acetaminophen

• Oral Opioids

Comparators

• Any

Outcomes

• Efficacy (pain hierarchy from highest to lowest priority)

o WOMAC pain subscale (Likert; 0–20) (VAS; 0–500)

o Pain during activity (VAS; 0–100)

o Pain during walking (VAS; 0–100)

o Global knee pain (VAS; 0–100)

o Pain at rest (VAS; 0–100)

o SF-36 (bodily pain (BP) subscale; 0–100)

o HAQ (pain subscale; 0–100/0–3), Lequesne algofunctional index (pain subscale; 0–8), AIMS (pain subscale; 0–10), Knee-Specific Pain Scale (KSPS), McGill Pain Questionnaire (pain intensity; 0–50), ASES (pain subscale; 10–100), SES (Schmerzempfindungsskala – pain perception scale)

o Pain at night (VAS; 0–100), pain during activity (NRS; 0–10), pain on walking (NRS; 0–10), number of painful days (days)

  1. AIMS Arthritis Impact Measurement Scale; ASES Arthritis Self-Efficacy Scale; HAQ Health Assessment Questionnaire; NRS numerical rating scale; OA osteoarthritis; SF-36 36-Item Short Form Survey; VAS Visual Analogue Scale; WOMAC Western Ontario and McMaster Universities Arthritis Index